Twist Bioscience (NASDAQ:TWST) Announces Quarterly Earnings Results

Twist Bioscience (NASDAQ:TWST) issued its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05, Briefing.com reports. The company had revenue of $75.30 million during the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The business’s revenue was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.06) earnings per share.

Twist Bioscience Trading Up 28.7 %

NASDAQ TWST traded up $9.20 during midday trading on Friday, hitting $41.21. The company had a trading volume of 4,457,624 shares, compared to its average volume of 975,484. The company has a market capitalization of $2.38 billion, a PE ratio of -11.42 and a beta of 1.64. The firm has a 50-day moving average price of $34.03 and a 200-day moving average price of $30.96. Twist Bioscience has a twelve month low of $11.81 and a twelve month high of $43.21.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TWST shares. Scotiabank lifted their price target on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a report on Monday, February 5th. Evercore ISI lifted their price target on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Robert W. Baird lifted their price target on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Barclays lifted their price target on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Twist Bioscience currently has an average rating of “Buy” and an average target price of $41.67.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the transaction, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the transaction, the chief executive officer now owns 516,409 shares in the company, valued at approximately $19,329,188.87. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Emily M. Leproust sold 1,128 shares of Twist Bioscience stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total value of $37,810.56. Following the completion of the transaction, the chief executive officer now owns 515,281 shares in the company, valued at approximately $17,272,219.12. The disclosure for this sale can be found here. Insiders sold 13,211 shares of company stock valued at $449,573 in the last three months. Corporate insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.